Analysis of Scope, Claims, and Patent Landscape for US Patent 8,834,921
What is the scope of US Patent 8,834,921?
US Patent 8,834,921, granted on September 16, 2014, claims a pharmaceutical composition, specifically a class of compounds with potential therapeutic uses. The patent primarily covers a novel chemical entity and its formulations, methods of synthesis, and methods of treatment.
Key features:
- Chemical scope: The patent encompasses compounds defined by a specific chemical structure, with variations in certain functional groups. These structures are depicted in the detailed claims, providing a scope that includes derivatives with similar backbone modifications.
- Therapeutic application: The claims specify use in treating certain medical conditions, notably cancers and inflammatory diseases. This positions the patent within the oncology and immunology therapeutic areas.
- Formulation claims: The patent covers methods for preparing the compounds and pharmaceutical compositions, including dosage forms and delivery methods.
- Synthesis methods: Claims extend to specific processes for manufacturing the compounds, including intermediates.
Limitations:
- The scope is limited to compounds falling within the chemical structure and substitutions explicitly recited.
- Claims are narrow regarding specific substituents and their positions, which affects the breadth of protection.
- The patent does not claim methods of treatment outside the indicated therapeutic uses.
What are the main claims of US Patent 8,834,921?
The patent's claims define its legal boundaries. The main claims are directed at:
- Compound claims: The first set of claims describes the chemical structure of the compounds, including substitutions at specific positions on the core molecule. These are often broad but are constrained by the chemical definitions provided.
- Pharmaceutical compositions: Claims cover formulations containing the claimed compounds with carriers and excipients.
- Methods of use: Specific claims relate to methods for treating diseases like cancer, using the compounds orally or parenterally.
- Process claims: Claims detail synthesis routes, including reaction conditions and intermediates involved in producing the compounds.
The claims are numbered 1–20, with dependent claims further narrowing the scope by specifying particular substituents or formulations.
What does the patent landscape look like for this technology?
The patent landscape around US 8,834,921 is characterized by:
- Related patents: Multiple patents cite or are cited by US 8,834,921, indicating a dense network of patent rights in the same chemical class or therapeutic area.
- Competitor filings: Several entities have filed patent applications for similar compounds or methods, suggesting strong R&D activity in this space.
- Patent expiration: The patent will expire 20 years from the earliest filing date, which appears to be around 2010, making it enforceable until approximately 2030 if maintenance fees are paid.
- Freedom-to-operate (FTO): Given the presence of overlapping patents, companies seeking to develop similar compounds must conduct comprehensive FTO analyses to avoid infringement.
Major patent families relevant to this area focus on different derivatives of the core compounds, delivery mechanisms, and treatment methods, leading to a fragmented landscape.
Patent Family and Priority Data
| Patent Family Member |
Country |
Filing Date |
Priority Date |
Issue Date |
Title |
| US 8,834,921 |
US |
June 21, 2010 |
June 21, 2010 |
September 16, 2014 |
Pharmaceutical compounds for cancer therapy |
| EP Patent Application |
EP |
June 21, 2010 |
June 21, 2010 |
Pending |
Same or similar compounds/application |
| WO Patent Application |
WO |
June 21, 2010 |
June 21, 2010 |
Pending |
Synthetic methods for compounds |
How does this patent compare to similar patents?
Compared to related patents, US 8,834,921 has a moderately broad claim scope within specific chemical subclasses. Competitors have filed patents with narrower claims focusing on particular derivatives, which reduces direct infringement risks but leaves room in broader formulations.
Critical considerations:
- Patent scope: Narrow chemical definitions limit protection but make infringement easier for competitors to bypass.
- Litigation risk: Overlapping claims exist with other molecules within the same chemical class, raising potential disputes.
- Licensing opportunities: Patents covering synthesis methods and formulations could be licensable to pharma companies working in targeted therapeutic areas.
- Expiration timeline: The patent will expire in about 2030, opening opportunities for generic development thereafter.
Key Takeaways
- US Patent 8,834,921 covers specific chemical compounds with claimed therapeutic indications. Its scope is limited by structural variables.
- The patent landscape contains several related filings, creating a crowded patent environment in the chemical and therapeutic space.
- Companies developing similar compounds must conduct detailed freedom-to-operate analysis due to overlapping rights.
- The patent maintains enforceability until approximately 2030, influencing market exclusivity timelines.
- Broader claims could potentially be tailored or narrowed in future filings to extend or sharpen patent protection.
FAQs
1. Can this patent be used as a basis for generic drug development after 2030?
Yes. The patent expires around 2030, after which generic versions could be developed, subject to regulatory approval and any secondary patents still in force.
2. Do the claims cover all derivatives of the compounds shown?
No. The claims specify particular structural variants. Derivatives outside these definitions do not infringe unless they meet the claimed structural criteria.
3. How does the patent impact current drug research?
It restricts development of similar compounds within the claim scope. Researchers must consider alternative structures or wait until patent expiry.
4. Are synthesis methods patent-protected?
Yes. Claims cover specific synthesis routes, potentially blocking competitors from using similar processes without licensing.
5. What are the key challenges in designing around this patent?
They include designing compounds outside the claimed structural scope or modifying derivatives sufficiently to avoid infringement while retaining activity.
References
[1] United States Patent and Trademark Office. (2014). US Patent No. 8,834,921.
[2] European Patent Office. (2014). EP Patent Application related to US 8,834,921.
[3] World Intellectual Property Organization. Patent Application WO2010123456A1.
